CN113260416A - 稳定性良好的医药组合物 - Google Patents

稳定性良好的医药组合物 Download PDF

Info

Publication number
CN113260416A
CN113260416A CN202080007515.8A CN202080007515A CN113260416A CN 113260416 A CN113260416 A CN 113260416A CN 202080007515 A CN202080007515 A CN 202080007515A CN 113260416 A CN113260416 A CN 113260416A
Authority
CN
China
Prior art keywords
pharmaceutical composition
compound
acid
dialysis
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080007515.8A
Other languages
English (en)
Chinese (zh)
Inventor
牧田良道
片冈大辅
久山和雄
浅野谦司
芝崎僚太郎
山本爱希子
我妻广贵
鹤田敦
鹰桥俊之
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of CN113260416A publication Critical patent/CN113260416A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080007515.8A 2019-04-03 2020-04-02 稳定性良好的医药组合物 Pending CN113260416A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-071168 2019-04-03
JP2019071168 2019-04-03
PCT/JP2020/015129 WO2020204117A1 (ja) 2019-04-03 2020-04-02 安定性の良好な医薬組成物

Publications (1)

Publication Number Publication Date
CN113260416A true CN113260416A (zh) 2021-08-13

Family

ID=72667705

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080007515.8A Pending CN113260416A (zh) 2019-04-03 2020-04-02 稳定性良好的医药组合物

Country Status (8)

Country Link
US (1) US20220142958A1 (enExample)
EP (1) EP3950058A4 (enExample)
JP (2) JP7166309B2 (enExample)
KR (1) KR20210146280A (enExample)
CN (1) CN113260416A (enExample)
BR (1) BR112021013002A2 (enExample)
CA (1) CA3124687A1 (enExample)
WO (1) WO2020204117A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117247339A (zh) * 2023-11-16 2023-12-19 潍坊富邦药业有限公司 一种烷基胺衍生物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781910A (zh) * 2010-03-04 2012-11-14 味之素株式会社 烷基胺衍生物
US20130072491A1 (en) * 2010-03-04 2013-03-21 Ajinomoto Co., Inc. Prophylactic or therapeutic agent for diabetes or obesity
JP2013063971A (ja) * 2011-09-02 2013-04-11 Ajinomoto Co Inc アルキルアミン誘導体を有効成分とする医薬
CN109200024A (zh) * 2017-07-07 2019-01-15 江苏恒瑞医药股份有限公司 西那卡塞药物组合物及其医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4154900B1 (en) 2009-07-29 2024-08-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
WO2014119643A1 (ja) 2013-01-31 2014-08-07 千寿製薬株式会社 澄明な水性液剤
CN107614486A (zh) * 2015-06-01 2018-01-19 味之素株式会社 烷基胺衍生物的制造方法及其制造中间体
TWI859130B (zh) * 2017-12-20 2024-10-21 日商Ｅａ製藥股份有限公司 維持透析下之二次性副甲狀腺機能亢進症之預防或治療用醫藥組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781910A (zh) * 2010-03-04 2012-11-14 味之素株式会社 烷基胺衍生物
US20130072491A1 (en) * 2010-03-04 2013-03-21 Ajinomoto Co., Inc. Prophylactic or therapeutic agent for diabetes or obesity
JP2013063971A (ja) * 2011-09-02 2013-04-11 Ajinomoto Co Inc アルキルアミン誘導体を有効成分とする医薬
CN109200024A (zh) * 2017-07-07 2019-01-15 江苏恒瑞医药股份有限公司 西那卡塞药物组合物及其医药用途

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117247339A (zh) * 2023-11-16 2023-12-19 潍坊富邦药业有限公司 一种烷基胺衍生物的制备方法
CN117247339B (zh) * 2023-11-16 2024-03-12 潍坊富邦药业有限公司 一种烷基胺衍生物的制备方法

Also Published As

Publication number Publication date
US20220142958A1 (en) 2022-05-12
JP2022186861A (ja) 2022-12-15
BR112021013002A2 (pt) 2021-10-13
JP2020169168A (ja) 2020-10-15
EP3950058A1 (en) 2022-02-09
EP3950058A4 (en) 2023-01-04
JP7166309B2 (ja) 2022-11-07
WO2020204117A1 (ja) 2020-10-08
CA3124687A1 (en) 2020-10-08
JP7549633B2 (ja) 2024-09-11
KR20210146280A (ko) 2021-12-03

Similar Documents

Publication Publication Date Title
US11357855B2 (en) Liquid formulation
RU2668882C2 (ru) Жидкая фармацевтическая композиция
US12016857B2 (en) Stable liquid vigabatrin pharmaceutical composition for oral dosage
TW202332447A (zh) 使用ＴＨＲ—β促效劑之肝臟病症之治療
KR102772900B1 (ko) 유지 투석 하의 2차성 부갑상선 기능 항진증의 예방 또는 치료용 의약 조성물
JP7549633B2 (ja) 安定性の良好な医薬組成物
HK40052036A (en) Pharmaceutical composition having favorable stability
HK40066239A (en) Pharmaceutical composition having favorable stability
HK40027549A (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
CA3085706C (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
HK40031634B (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
HK40031634A (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
CN118105387A (zh) 一种伏诺拉生氟比洛芬药物组合物及其制备方法
HK1208372B (en) Liquid formulation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40052036

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination